Sorted By Test Name - Mayo Medical Laboratories

SECOS
8243
FSEC
90173
sensitization to particular allergens prior to beginning immunotherapy, and to investigate the specificity of
allergic reactions to insect venom allergens, drugs, or chemical allergens.
Interpretation: Detection of IgE antibodies in serum (Class 1 or greater) indicates an increased
likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be
responsible for eliciting signs and symptoms. The level of IgE antibodies in serum varies directly with the
concentration of IgE antibodies expressed as a class score or kU/L.
Reference Values:
Class IgE kU/L Interpretation
0 Negative
1 0.35-0.69 Equivocal
2 0.70-3.49 Positive
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by RA McPherson, MR Pincus. New York, WB Saunders
Company, 2007, Chapter 53, Part VI, pp 961-971
Secobarbital, Serum
Clinical Information: Secobarbital is a short-acting barbiturate with hypnotic properties used as a
preanesthetic agent and in the short-term treatment of insomnia.(1,2) Secobarbital is administered orally.
The duration of its hypnotic effect is about 3 to 4 hours. The drug distributes throughout the body, with a
volume of distribution (Vd) of 1.6 to 1.9 L/kg, and about 46% to 70% of a dose is bound to plasma
proteins. Metabolism takes place in the liver primarily via hepatic microsomal enzymes. Secobarbital's
half-life is about 15 to 40 hours (mean: 28 hours).(2,3)
Useful For: Monitoring secobarbital therapy
Interpretation: Therapeutic concentration: 1.0 to 2.0 mcg/mL Toxic concentration: >5.0 mcg/mL
Reference Values:
Therapeutic concentration: 1.0-2.0 mcg/mL
Toxic concentration: >5.0 mcg/mL
Concentration at which toxicity occurs varies and should be interpreted in light of clinical situation.
Clinical References: 1. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 10th
edition. New York, McGraw-Hill Book Company, 2001 2. Teitz Textbook of Clinical Chemistry and
Molecular Diagnostics. 4th edition. Edited by CA Burtis, ER Ashwood, DE Bruns. St. Louis, MO,
Elsevier Saunders, 2006, p 1091 3. Disposition of Toxic Drugs and Chemicals in Man. 7th edition. Edited
by RC Baselt. Foster City, CA, Biomedical Publications, 2004, p 1254
Secretin
Clinical Information: Secretin is a 27 amino acid basic peptide produced by S cells and released by
acid delivered into the duodenum. Secretin is released into the blood when duodenal pH drops below 4.
Secretin shares structural similarity with Glucagon, Gastric Inhibitory Polypeptide, Vasoactive Intestinal
Polypeptide, PHIM, and Growth Hormone- Releasing Hormone. Secretin is a potent stimulus for
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1566